CompletedNCT01376076
Heart-Rhythm Effects of Cariprazine in Schizophrenia
About this title
Read the official source — NCT01376076Medication studyAges 18–50United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Glendale and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateJune 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 129
- Sponsor
- Forest Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT01376076
- Official title
Show the full official title
Evaluation of the Effects of Sequential Multiple-Dose Regimens of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glendale · Long Beach · Willingboro
1 more locations
- Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Forest Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine and Risperidone/Moxifloxacin.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
